that can possibly serve as viral reservoirs so that the mechanisms by which such reservoirs are maintained can be identified. This would facilitate the development of strategies for eliminating these reservoirs, particularly in individuals treated with highly active antiretroviral therapy (ART) 5 . Ideally, a method to identify changes in virus localization would be minimally invasive as well as specific, sensitive and amenable to repeated application. Here we describe the application of whole-body imaging to the detection and localization of sites of SIV infection in chronically infected, ART-treated and EC macaques.
results
We hypothesized that the higher sensitivity and image quality of 64 Cu-based positron emission tomography (PET) over that of single-photon emission computer tomography 6 could be exploited to detect the major target tissues infected by SIV or HIV by scanning the entire body [7] [8] [9] [10] . To test this hypothesis, we employed the SIV-infected rhesus macaque as a model of pathogenic HIV infection 11, 12 and chose the glycoprotein Gp120 as the in vivo target 7 .
development of the immunoPet probe
We selected the SIV Env protein-specific monoclonal antibody (mAb) clone 7D3 as the basis of the probe because of its broad SIV Env specificity [13] [14] [15] . 7D3 binds the CCR5 binding site of Gp120 and prevents syncytia formation in vitro with SIV MACCP-MAC , although it does not affect soluble CD4 binding or neutralize SIV mac239 (ref. 13) . Furthermore, three 7D3 molecules can bind to the trimeric Env of SIV MACCP-MAC and SIV MAC239 (ref. 15) . To mitigate the immunogenicity of murine antibodies (probe antibodies were not detected after two administrations; data not shown), decrease nonspecific interactions and enable the chelation of 64 Cu, the mAb was modified with linear 10-kDa poly(ethylene glycol) (PEG) 16 through standard succinimidyl ester-amino chemistry and the chelator DOTA NHS (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono), which has been demonstrated to be stable in humans and mice for at least 72 h (refs. 17,18) .
We performed in vitro assays to validate the probe (Supplementary Fig. 1 ). First, we incubated the 64 Cu-labeled radiotracer with varying percentages of SIV1C cells and uninfected Hut78 cells (Supplementary Fig. 1a) , demonstrating a linear binding response with decreasing percentages of infected cells, as measured with a gamma counter. Next we measured gamma counts from equal aliquots of cryopreserved and thawed splenocytes and lymph node cells, collected at necropsy from uninfected and SIV-infected animals ( Supplementary Fig. 1b ). The data demonstrate that even after a freeze-thaw cycle, the 7D3-PEG-64 Cu-DOTA probe bound specifically to infected cells. Subsequently, we performed a competition assay whereby 'cold' 7D3-PEG-DOTA was used to compete with bound 'hot' 7D3-PEG-64 Cu-DOTA from SIV1C and Hut78 cells, demonstrating epitope-specific binding of the probe (Supplementary Fig. 1c) . In order to assess differences between 7D3-PEG-DOTA-and 7D3-PEG-DyLight 650-labeled probes (used in flow cytometry assessments), we used both probes to label SIV1C cells, demonstrating specific binding (Supplementary Fig. 1e ). This experiment showed that the fluorescent probe binds with the same efficacy as the 7D3-PEG-DOTA (cold) probe. We then assessed the DyLight 650-labeled probe, using flow cytometry for its binding to SIV1C cells in the presence of serum and SIV-specific antibodies generated during infection (Supplementary Fig. 1f ). Although there was less binding of 7D3 in the presence of the pre-and post-infection serum than with monkey serum absent, we noted specific binding to SIV1C relative to uninfected Hut78 cells.
characterization of chronic siV infection
To generate images of SIV dissemination in vivo, we injected the 7D3-PEG-64 Cu-DOTA probe (labeled with 1-3.5 mCi/mg 64 Cu) into rhesus macaques intravenously. We tested probe stability by pelleting virus from the plasma of the infected and uninfected animals and measuring the radioactivity (Supplementary Fig. 1d ). These data demonstrate that specific probe binding to virus was still possible 24 h after injection of the probe. We found PET and computed tomography (CT) imaging (hereafter PET/CT) in both viremic and control animals to be optimal 24-36 h after injection (data not shown). We then imaged macaques chronically infected with SIV MAC239 and uninfected control Table 1) . We generated standardized uptake value (SUV) maps for each PET and corresponding CT image using OsiriX software (Fig. 1a,b and Supplementary Fig. 2a-f) . SUV is essentially the measured activity within a region of interest, normalized by the radioactive dose divided by the subject's weight. In the viremic animals, SUV values greater than those observed in the control cases were localized to the gastrointestinal (GI) system, specifically within the ileum, jejunum and colon, and the axillary and inguinal lymph nodes, correlating with previously reported findings 12, [19] [20] [21] . We also detected uptake within the lungs, a less well-characterized site of viral infection 22 . As can be seen in detail in slice sequences for monkeys Viremic 1 and 2, the uptake followed the contours of the ileum and colon ( Supplementary  Fig. 3a,b) . We also consistently detected antibody uptake within the nasal cavity, likely reflective of the nasal-associated lymphoid tissue (NALT) or nasal turbinates (Fig. 1a) , an area that has received little attention as a source of viral replication. In males, we frequently observed uptake within the genital tract, specifically in the vas deferens and epididymis, corroborating previous reports [23] [24] [25] . In contrast to a previous report 26 , infection of epithelial cells was not detected in the male genital organs. In the uninfected monkeys, background was evident within the liver, heart, kidneys and spleen, which is typical of antibody-based radiotracers 17, 18 . It should be noted, however, that SUVs were significantly higher in infected animals than in control cases in each of these organ systems, indicating specific uptake (P < 0.05, Kruskal-Wallis test; Supplementary Table 2) . A sequence of frontal slice images obtained on the uninfected monkey Control 1 after administration of 64 Cu-7D3 demonstrates that uptake was minimal throughout the GI tract and that background was restricted to the heart, liver, kidneys and spleen ( Supplementary Fig. 3c ).
Pet quantification and comparison with qrt-Pcr and ihc
We verified the imaging signal data by qRT-PCR and through the examination of sections of the specific tissue of interest using immunohistochemistry (IHC) for SIV Gag protein (Fig. 1c,d and Supplementary Fig. 2 ). These confirmatory studies used rectal biopsy tissues obtained immediately after imaging and/or tissues obtained post-mortem. On the basis of the IHC data, the GI tract, lymph nodes and spleen all contained infiltrating SIV-infected cells of lymphocyte or macrophage morphology. Negative control tissue (Fig. 1d) did not contain any detectable signal using the same IHC protocol. We also performed qRT-PCR using tissue samples from the colon, small bowel, spleen and inguinal and axillary lymph nodes for all of the chronically infected animals and controls (Fig. 1e) . Corroborating our IHC results, we detected viral RNA in all cases, with the highest levels in the colon; we did not detect RNA in the controls. In addition, we quantified the 64 Cu-radioactivity associated with aliquots of rectal biopsies from viremic monkeys Viremic 1 and 2 and uninfected Controls 1 and 2 with a gamma counter. The signal from these tissues, normalized for the mass of the biopsy and the total amount of radioactivity administered, was 17.6 times higher on average in infected animals ( Fig. 1f) than in both controls, providing additional confirmation of the specificity of the PET imaging.
To compare the PET results from viremic animals to those of the controls, we quantified the data using SUV (Fig. 1a,b ,e,g and Supplementary Fig. 2 ). We chose volumes of interest in the PET/CT fusion images by outlining the organ manually in the CT Articles images throughout the image slices. Using the organ volume as the region of interest (ROI), we then determined the maximum SUV within that organ and compared the SUV max within viremic and uninfected animals with the qRT-PCR results from the corresponding colon, small bowel, spleen and inguinal and axillary lymph nodes of the same animal (Fig. 1e) . These data suggest that the PET SUV max values mimic the general trends of the PCR data. For the spleen, which tends to have higher background uptake, the SUV max minus background is a more relevant comparison with the qRT-PCR data. It should be pointed out that the SUV data are unlikely to match the PCR data precisely, as protein and RNA expression levels may differ. Next, to address the specificity of the PET signals, we compared the SUV max measurements for various tissues from chronically infected and uninfected macaques injected with either the modified 7D3-labeled antibody or with a labeled isotype control antibody ( Fig. 1g and Supplementary Fig. 2g) . The data suggest that there is increased uptake within organ systems likely to contain virus or virally infected cells and tissue. For each group of animals, we then performed an overall comparison of the PET measurements that included the signals of all organs, applying a fully nested hierarchical ANOVA model for the SUV max response. The null hypothesis for the comparison was that the viral status of the animal and the injected probe would not influence the imaging results. We found that the viremic animals were significantly different from the uninfected controls (P = 7.39 × 10 −6 ). However, animals within each group, infected or uninfected, were not significantly different from each other (P = 0.89). The analysis also showed that both the infection status (animal group) and organs contributed significantly to the SUV max value. We found that for the chronically viremic animals and both control groups, the measurements for each organ within each group were significantly different from each other, yielding P values of 1.4 × 10 −9 , 7.1 × 10 −27 and 4.78 × 10 −19 , respectively. Furthermore, when we applied the Kruskal-Wallis test for each organ separately (Supplementary Table 2) , the signals measured in viremic and uninfected controls were statistically distinct except for in muscle.
Another method of assessing specific uptake for a particular organ is to examine the dynamics of uptake. Owing to logistics, we scanned animals at 12, 24 and/or 36 h after injection and plotted the ratios of the average SUV max values at each time point for each organ (Fig. 1h) . When we compared the viremic monkeys with the aviremic controls, all of the ratios in viremic animals were higher-typically above 0.6, with the GI tract giving values >1.0-indicating continued specific uptake of the probe. The decay rate and SUV max values in whole blood (SUV max ≈ 0.3-0.4; data not shown) were similar to those of muscle, and remained similar between groups. We did not detect uptake in the central nervous system, probably because of probe exclusion by the blood-brain barrier 27 .
siV localization before and during antiretroviral therapy
In order to confirm the sensitivity of this method and its ability to track SIV replication anatomically during treatment, we first imaged three chronically infected animals (ART 1, ART 2 and ART 3) 36 h after injection with our modified 7D3 probe and then initiated them on ART (20 mg PMPA (9-(2-phosphonomethoxypropyl) adenine) per kg body weight per day (mg per kg per d) and 50 mg per kg per d emtricitabine (FTC) each subcutaneously and 100 mg/d for 40 d of integrase inhibitor L-870812) ( Fig. 2  and Supplementary Fig. 4 ). All three animals were aviremic by Fig. 5 ) and imaged again after 5 weeks on ART (Fig. 2 and Supplementary Fig. 4) . Prior to treatment, there was measurable SIV signal localized within the GI tract, NALT, genital tract and axillary and inguinal lymphoid tissue. After 34 d of treatment, all organ systems exhibited decreased uptake (Fig. 2a,b, Supplementary Fig. 4 and Supplementary  Table 3a) . However, there was residual signal (above the background) in all organ systems, with moderate SUV max values still remaining in the colon, spleen, male genital tract, NALT and individual lymph nodes for specific animals. In none of the cases did the SUV max decrease to our measurable limit (background). To assess the statistical significance of the SUV max measurements, we performed a hierarchical ANOVA analysis as described above. The differences between the SUV max data before and after treatment from all of the organs imaged were significant, with a P value of 0. In a pairwise comparison, ART 1 and ART 3 were significantly different from ART 2 (P = 0.0027), demonstrating the individual variation in ART treatment.
To verify the imaging results, we performed qRT-PCR on multiple tissue samples and compared the data directly with SUV max data ( Fig. 2c and Supplementary Fig. 4c ). The samples included colon, small bowel, spleen, and right and left inguinal and axillary lymph nodes; these were collected at necropsy performed after 39 or 40 d on ART. Even though our PET procedure measures Env protein and qRT-PCR detects viral RNA, residual virus or infected cells were indeed present in the locations identified by PET. Both the spatial variation within an animal and the variation between animals suggested by PET was confirmed with qRT-PCR data ( Supplementary Fig. 6 and Supplementary Table 3b) , with two-orders-of-magnitude variation within an organ and between animals. Additionally, the nasal turbinate, genital tract and lung samples were all positive for viral RNA (Supplementary Table 3b) , indicating virus localization during both chronic and treated conditions, a similar result to that observed in viremic animals.
siV localization in elite controllers
We then applied the methodology to SIV-infected ECs. ECs are individuals that naturally suppress SIV (or HIV) replication to undetectable levels in plasma for extended periods of time without antiretroviral intervention 1, 2 . Given the challenges studying viral persistence in these animals, they were an ideal test for our approach. EC monkeys exhibited detectable uptake ( Fig. 3 and  Supplementary Fig. 7) within the GI tract, genital tract, NALT, lungs, spleen and axillary lymph nodes. These imaging data were supported by IHC in biopsy samples (Supplementary Fig. 7,   Supplementary Table 2 and Supplementary Note). In ECs, the uptake was restricted to smaller regions or foci as compared to viremic animals. When quantified, the SUV max organ signal appeared to approximate the results in viremic animals (Fig. 3b) . However, when we applied a hierarchical ANOVA, we found that overall the PET SUV max data for the viremic animals were statistically distinct from those of the ECs and the control animals (P = 2.78 × 10 −5 ). To clarify the differences between the ECs and viremic animals, we measured the SUV mean within the GI tract and compared the voxel fractions (fraction of total volume of GI tract) (Fig. 4 and Supplementary Fig. 8 ).
The GI tract values in the viremic animals were 2.1 and 6.38 times greater than in the EC animals for SUV mean and voxel fraction, respectively. Thus, although the viremic macaques and ECs had regions of comparably high uptake, in ECs, this was spatially restricted to much smaller volumes, and therefore the overall probe uptake was lower. We calculated additional metrics quantifying the spatial distributions within the GI tract, which further supported this conclusion (Fig. 4a,b and Supplementary Note).
discussion
We describe the development of a non-invasive, sensitive immuno PET radiotracer and an approach to define the localization of SIV-infected tissue and free virus within live, chronically viremic, ART-treated and EC animals. The method can be repeated within the same animals (for example, before and during ART) without any adverse effect. In viremic animals, infection was concentrated within the mucosa of the gut, reiterating that these tissues are a major site of SIV replication 12, 20, 21 . However, we also observed discrete areas of virus replication, confirmed by qRT-PCR and IHC, both in nasal-associated tissues (post-ART) and in the reproductive tract of male animals. Within chronically infected, aviremic, ART-treated as well as EC animals, the methodology was able to detect residual virus, corroborated by qRT-PCR data. Thus, this approach provides the ability to identify novel areas of virus replication that may otherwise be difficult to sample in live animals. It may also provide a powerful tool to monitor the kinetics of viral replication in tissues over time during the application of novel therapeutic approaches. With the current efforts toward HIV eradication or functional cure, we believe that this method can be useful for determining organ-specific efficacy, which is crucial to the elimination of virally infected cells. 
Articles
Our data also indicate that care must be taken when analyzing biopsies from aviremic subjects, especially ART-treated subjects, which may result in erroneous conclusions due to sampling ( Supplementary Fig. 6 and Supplementary Table 3b) . The detailed study of the cellular composition of these specific foci of infection, combined with site-specific drug metabolite levels and aided by the ability to image these specific sites, will likely be key to the development of directed therapies aimed at clearing infection from these sites in both controllers and individuals under ART [28] [29] [30] .
Although additional refinements to improve contrast and uptake are ongoing, we think that the methodology should be translatable to humans in the future because of the availability of anti-Env HIV antibodies 31 and because the imaging approach is based on technologies already used in the clinic 17, 18 . It is applicable for studies investigating the eradication of HIV infection and targeting of virus reservoirs 28, 32 . Moreover, use of this technology during acute SIV infection may provide improved delineation of spatial kinetics of viral spread based on the route of infection and allow the identification of stages at which interruption of infection may be targeted using prophylactic methods 33 .
methods
Methods and any associated references are available in the online version of the paper. online methods Antibody production. The monoclonal antibody secreting hybridoma (clone 7D3) was provided by J.H. 13 . Preparation and purification of 100 mg of 7D3 was performed by R. Mittler of the Emory CFAR Immunology Core using standard methods. The isotype control antibody was purchased from Innovative Research, catalog # IR-MS-GF-ED (Endotoxin Depleted Mouse IgG).
Antibody modification for in vivo imaging. To conjugate 1,4,7, 10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono (DOTA NHS) and poly(ethylene glycol) esters (PEG ester) to surface lysine residues of 7D3, molar ratios of 60:1 and 20:1, respectively, were used. Briefly, 1 mg of clone 7D3 mAb (at 3.8 mg/ml) was buffer exchanged with 0.1 M phosphate buffer (EMS), pH 7.3, plus Chelex 100 (Bio-Rad) using a 10-kDa Amicon spin column (Millipore). Then 1 µl of 0.5 M DOTA NHS ester (Macrocyclics) in phosphate buffer and Chelex 100 and 32 µl of 5 mM m-PEG-SMB 10K (Nectar), also in phosphate buffer and Chelex 100, were added and reacted for 4 h at RT on a rotator. Unconjugated reagents were removed using 30-kDa Amicon spin columns in phosphate buffer plus Chelex 100. Samples were quantified via UV-VIS spectroscopy, and the conjugations verified via gel electrophoresis using Tris-acetate gels in TA running buffer with SDS (Invitrogen). The modified 7D3 antibody was then divided into aliquots and lyophilized for storage.
Radiolabeling. Lyophilized PEG-DOTA-7D3 was resuspended in Chelexed 0.1 M NH 4 OAc, pH 5.5 (Sigma). Copper (II)-64 chloride (Washington University) was diluted similarly; they were then mixed together at a ratio of approximately 5 mCi/mg and incubated at 37 °C for 1 h. The antibody conjugates typically labeled in the range of 1-3.5 mCi/mg per dose. Each dose was buffer exchanged with pharmaceutical-grade saline three times using a 10-kDa centrifugal filter to a final volume of 20 µl. The conjugated mAb was then added to 1 ml of pharmaceutical-grade sterile saline in a sterile glass vial. Uptake was confirmed on an aliquot using thin layer chromatography. The labeled antibody conjugates gave values in the range of 1-3.5 mCi/mg.
In vitro 7D3-PEG-64 Cu-Dota probe specificity test. SIV1C cells with one integrated copy of SIVmac251 and uninfected parental Hut78 cells (ATCC TIB-161) were cultured in RPMI 1640 supplemented with penicillin-streptomycin and 10% FBS. 24 h before assaying, the cell cultures were supplied with 100 U/ml of rMamu IL-2-Fc to induce increased expression of SIV Gp120 on the surface of SIV1C cells 34 . For staining, tubes were set up with 500,000 cells containing varying mixtures of SIV1C and Hut78 cells (100%, 75%, 50%, 25% and 0% SIV1C). 200 ng of freshly radiolabeled 7D3-PEG-64 Cu-DOTA were added to each tube of cells suspended in 200 µl of PBS and incubated for 15 min at room temperature. The tubes were then washed three times with 2 ml of PBS and read in a Packard gamma counter. All cell lines used were free of mycoplasma.
Competition of 'cold' 7D3-PEG-DOTA with 7D3-PEG-64
Cu-DOTA. 250,000 SIV-1C or control Hut78 cells were suspended in tubes with 200 ng of radiolabeled 7D3-PEG-64 Cu-DOTA followed by the immediate addition of varying amounts of cold 7D3-PEG-DOTA (0, 56.3, 237.5, 950 and 3,800 ng). Incubation, washing and reading of the tubes radioactivity were done as described above.
Ex vivo labeling of primary cells with 7D3-PEG-64 Cu-DOTA.
Cryopreserved lymph node cells and splenocytes from both SIV-positive and SIV-negative rhesus macaques collected at necropsy were thawed, washed in PBS and counted. 5 million cells for each tissue were suspended in 200 µl PBS and 500 ng of 7D3-PEG-64 Cu-DOTA, and 10 µl of serum from an SIV negative animal that were heat inactivated for 30 min at 56 °C. The cells were then incubated for 15 min at room temperature followed by four washes with 2 ml of PBS and read in a Packard gamma counter. 38, 39 .
